1. Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement.
- Author
-
Liu Y, Wang X, Zhou J, Shi S, Shen T, Chen L, Zhang M, Liao C, and Wang C
- Subjects
- Animals, Antibodies, Viral blood, Cytokines metabolism, Disease Models, Animal, Drug Compounding, Immunity, Cellular drug effects, Immunity, Humoral drug effects, Influenza Vaccines chemistry, Influenza Vaccines immunology, Lung immunology, Lung pathology, Lung virology, Lymphocyte Activation drug effects, Mice, NIH 3T3 Cells, Oligopeptides chemistry, Oligopeptides immunology, Orthomyxoviridae Infections immunology, Orthomyxoviridae Infections pathology, Orthomyxoviridae Infections virology, Vaccination, Vaccines, Subunit administration & dosage, Vaccines, Subunit chemistry, Vaccines, Subunit immunology, Drug Carriers, Epitopes, Immunogenicity, Vaccine, Indoles chemistry, Influenza A Virus, H9N2 Subtype immunology, Influenza Vaccines administration & dosage, Lung drug effects, Nanoparticles, Oligopeptides administration & dosage, Orthomyxoviridae Infections prevention & control, Polymers chemistry
- Abstract
The protection of current influenza vaccines is limited due to the viral antigenic shifts and antigenic drifts. The universal influenza vaccine is a new hotspot in vaccine research that aims to overcome these problems. Polydopamine (PDA), a versatile biomaterial, has the advantages of an excellent biocompatibility, controllable particle size, and distinctive drug loading approach in drug delivery systems. To enhance the immunogenicities and delivery efficiencies of H9N2 avian influenza virus (AIV) epitope peptide vaccines, PDA nanoparticles conjugated with the BPP-V and BP-IV epitope peptides were used to prepare the nano BPP-V and BP-IV epitope peptide vaccines, respectively. The characteristics of the newly developed epitope peptide vaccines were then evaluated, revealing particle sizes ranging from approximately 240 to 290 nm (PDI<0.3), indicating that the synthesized nanoparticles were stable. Simultaneously, the immunoprotective effects of nano BPP-V and BP-IV epitope peptide vaccines were assessed. The nano BPP-V and BP-IV epitope vaccines, especially nano BP-IV epitope vaccine, quickly induced anti-hemagglutinin (HA) antibody production and a sustained immune response, significantly promoted humoral and cellular immune responses, reduced viral lung damage and provided effective protection against AIV viral infection. Together, these results reveal that PDA, as a delivery carrier, can improve the immunogenicities and delivery efficiencies of H9N2 AIV nano epitope vaccines, thereby providing a theoretical basis for the design and development of PDA as a carrier of new universal influenza vaccines., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Liu, Wang, Zhou, Shi, Shen, Chen, Zhang, Liao and Wang.)
- Published
- 2021
- Full Text
- View/download PDF